T he overexpression of human epidermal growth factor receptor 2 (HER2) in breast cancer results in more aggressive disease with a poor prognosis. 1 The humanized anti-HER2 monoclonal antibodies pertuzumab and trastuzumab are more active in combination than alone because of more comprehensive signaling blockade. 2, 3 We investigated combination therapy with docetaxel for first-line treatment of HER2-positive metastatic breast cancer in the Clinical Evaluation of Pertuzumab and Trastuzumab (CLEOPATRA) trial. Analysis of the primary end point showed that patients who received pertuzumab, trastuzumab, and docetaxel (pertuzumab group) had a significantly longer median progression-free survival, as assessed by independent reviewers, than did those who received placebo, trastuzumab, and docetaxel (control group) (hazard ratio favoring the pertuzumab group, 0.62). 4 The second interim analysis of overall survival confirmed significantly longer survival in the pertuzumab group (hazard ratio, 0.66). 5 Safety profiles (including cardiac) were similar and consistent across the two study groups and the analysis time points. [4] [5] [6] Here we report follow-up data at a median of 50 months regarding overall survival, investigator-assessed progression-free survival and safety, and independently assessed duration of response.
Me thods

Study Design and Patients
In this randomized, double-blind, placebo-controlled, phase 3 trial, 4,5 we enrolled patients who were at least 18 years of age with locally recurrent, unresectable, or metastatic HER2-positive breast cancer that was centrally confirmed. Eligible patients had a left ventricular ejection fraction (LVEF) of 50% or more at baseline, had an Eastern Cooperative Oncology Group performance status of 0 or 1, and had received no more than one hormonal treatment for metastatic disease. Adjuvant or neoadjuvant chemotherapy with or without trastuzumab was allowed. Patients were excluded if they had central-nervous-system metastases, if the LVEF was less than 50% during or after previous trastuzumab therapy, or if they had received other anticancer therapy (with the exception of one previous hormonal regimen) or had a cumulative exposure of more than 360 mg of doxorubicin per square meter of body-surface area or its equivalent. All randomization and masking processes and assessments have been reported previously. 4, 5 After significant improvement in overall survival was reported with pertuzumab (Perjeta, F. Hoffmann-La Roche and Genentech), 5 patients who were still receiving the placebo combination in whom disease had not progressed were invited to cross over to receive pertuzumab. Overall survival results presented here are from the intention-to-treat population; therefore, data from crossover patients were analyzed in the control group. Two sensitivity analyses of overall survival were conducted: one in which data from crossover patients were censored at the time of the first pertuzumab dose and one in which these patients were excluded from the results. Postcrossover safety data are reported separately.
The CLEOPATRA trial was performed in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki. Protocol approval was obtained from an independent ethics committee at each study site. All patients provided written informed consent.
Study Oversight
The study was designed by the senior academic authors and representatives of the sponsors, F. Hoffmann-La Roche and Genentech. Data were collected by the sponsors and analyzed in collaboration with the senior academic authors, who vouch for the completeness and accuracy of the data and analyses and for the fidelity of the study to the protocol. The protocol, including the statistical analysis plan, is available with the full text of this article at NEJM.org. All investigators participating in the study agreed to confidentiality regarding the data. The first author prepared the initial draft of the manuscript with assistance from a medical writer employed by Health Interactions and funded by F. Hoffmann-La Roche. All authors contributed to subsequent drafts and made the decision to submit the manuscript for publication.
Study Procedures
Study drugs were administered intravenously every 3 weeks. Pertuzumab (at a dose of 840 mg) or placebo was given on day 1 of cycle 1, followed by 420 mg on day 1 of each subsequent cycle; trastuzumab (Herceptin, F. Hoffmann-La Roche and Genentech) at a dose of 8 mg per kilogram of 726 body weight was administered on day 2 of cycle 1, followed by 6 mg per kilogram on day 1 of the remaining cycles. Pertuzumab or placebo and trastuzumab were administered until disease progression or the occurrence of unmanageable toxic effects; dose reductions were not allowed. Docetaxel was given at a dose of 75 mg per square meter on day 2 of cycle 1 and on day 1 of the remaining cycles; at least six cycles were recommended, but fewer cycles were allowed in case of disease progression or unmanageable toxic effects, and more cycles were allowed at the discretion of the investigator or patient. Docetaxel could be escalated to 100 mg per square meter if there were no unmanageable toxic effects and could be reduced by 25% in the case of myelosuppression, hepatic dysfunction, or other toxic effects. Growth-factor support could be added according to prescribing information and the guidelines of the American Society of Clinical Oncology. 7 No concurrent hormonal therapy was allowed before disease progression.
Study End Points
Since independent review of progression-free survival and the objective response rate were stopped after the first analysis, 4 we report updated data on the secondary end points of overall survival (time from randomization to death from any cause) and investigator-assessed progression-free survival, which was defined as the time from randomization to the first documented radiographic evidence of progressive disease, according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0, 8 or death from any cause within 18 weeks after the last investigator assessment of tumors. We also present the duration of response from the time of the data cutoff for the primary analysis.
Statistical Analysis
Data for patients who were alive or lost to followup were censored at the last date they were known to be alive or at the time of randomization plus 1 day, if no information was available after baseline. For the final analysis of overall survival, we determined that the study would have a power of 80% to detect a 33% improvement in the pertuzumab group (hazard ratio for death from any cause, 0.75) after the occurrence of 385 deaths. The statistical stopping boundary for each interim analysis was established with the use of the O'Brien-Fleming approach and was crossed at the second interim analysis; consequently, this final analysis is considered to be descriptive.
We used the log-rank test to compare overall survival between the two treatment groups, with stratification according to status with respect to adjuvant or neoadjuvant chemotherapy and geographic region. Kaplan-Meier analyses were used to estimate medians. A Cox proportional-hazards model was used to estimate hazard ratios and 95% confidence intervals with the same stratification factors.
Subgroup analyses were performed to ensure robustness of the treatment effect across prespecified categories. All analyses were performed with the use of SAS software, version 8.2 (SAS Institute).
R esult s
Study Population
Patients were enrolled from February 12, 2008, through July 7, 2010. The cutoff for data collection for this analysis was February 11, 2014 . (Enrollment and randomization are shown in Fig. 1 .) Baseline characteristics were similar in the two study groups; 630 patients (88.0%) had visceral disease. 4, 5 A total of 389 patients had died at the time of this analysis. Median follow-up was 49.5 months (range, 0 to 70) in the pertuzumab group and 50.6 months (range, 0 to 69) in the control group. After the interim analysis of overall survival in May 2012, investigators were informed about study-group assignments. Between July and November 2012, a total of 48 of the 406 patients (11.8%) in the control group crossed over to receive pertuzumab.
Overall Survival
Intention-To-Treat Population
Deaths were reported in 168 of 402 patients (41.8%) in the pertuzumab group and in 221 of 406 patients (54.4%) in the control group (hazard ratio favoring the pertuzumab group, 0.68; 95% confidence interval [CI], 0.56 to 0.84; P<0.001) ( Fig. 2A) All patients who underwent randomization were included in the intention-to-treat population, and patients who received at least one dose of a study drug were included in the safety analysis. Reasons for withdrawals are shown. Included in the safety population are nine patients in the control group who received pertuzumab and one patient in the pertuzumab group who received placebo, as indicated.
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Sensitivity Analyses
The 48 patients without disease progression who opted to cross over from the control group to receive pertuzumab had all been receiving treatment for 2 years or longer. When their data were censored at the time of the first pertuzumab dose, the median overall survival was 56. 
Investigator-Assessed Progression-Free Survival
In the investigator-assessed intention-to-treat analysis, events occurred in 284 of 402 patients (70.6%) in the pertuzumab group and 320 of 406 patients (78.8%) in the control group (hazard ratio, 0.68; 95% CI, 0.58 to 0.80; P<0.001) (Fig. 3A) .
The results of subgroup analyses were consistent (Fig. 3B) . The medians were unchanged from the May 2012 interim analysis (18.7 months in the pertuzumab group and 12.4 months in the control group, an improvement of 6.3 months). 5
Duration of Response
The duration of response was independently assessed in patients with a confirmed partial or complete response at the time of the primary analysis (275 patients in the pertuzumab group and 233 in the control group). Median durations of response were 20.2 months in the pertuzumab group (95% CI, 16.0 to 24.0) and 12.5 months in the control group (95% CI, 10.0 to 15.0).
Breast-Cancer Therapies after Discontinuation of study treatment
Among the 704 patients in the intention-to-treat population who received breast-cancer therapies after the discontinuation of the study treatment, the proportions of patients who received various drugs was balanced in the two study groups (Table 1). A total of 72.9% patients in the pertuzumab group and 71.5% in the control group received HER2-targeted therapy.
Treatment Exposure
The median number of study-treatment cycles received by patients in the safety population was 24 in the pertuzumab group (range, 1 to 96; 197 patients received more than the median number) and 15 in the control group (range, 1 to 67). Patients who crossed over to the pertuzumab group received a median of 22.5 cycles of pertuzumab (range, 1 to 28), which was similar to the median number of cycles received by patients in the pertuzumab safety population. Docetaxel exposure did not change between data cutoffs (median, 8 cycles in each group).
Side-Effect Profile and Cardiac Safety
All Patients
Rates of adverse events remained consistent with those in the primary analysis, with headache, upper respiratory tract infection, and muscle spasm reported as new adverse events with a difference of at least 5 percentage points between groups. Most events were grade 1 or 2 and occurred during docetaxel administration and declined after discontinuation. A list of the most common adverse events of all grades that occurred at a frequency of 25% or more or showed a difference of at least 5 percentage points between study groups overall is provided in Table S1 in the Supplementary Appendix. Table 2 shows the rates of the same most common adverse events after the discontinuation of docetaxel. The rate of left ventricular dysfunction, as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0, and the New York Heart Association, 6 was somewhat lower in the pertuzumab group than in the control group (6.6% [27 of 408 patients] vs. 8.6% [34 of 396 patients]). There Panel A shows Kaplan-Meier estimates of overall survival in the intention-to-treat population, stratified according to adjuvant or neoadjuvant therapy and geographic region. The median overall survival among patients receiving pertuzumab, trastuzumab, and docetaxel (pertuzumab group) was 56.5 months, 15.7 months longer than survival among patients receiving placebo, trastuzumab, and docetaxel (control group). The tick marks indicate censoring events. Panel B shows hazard ratios and 95% confidence intervals for overall survival in all prespecified subgroups according to baseline characteristics, without stratification. Race or ethnic group was determined by the investigator. "Other" includes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, and other populations. A grade of 3+ on immunohistochemical (IHC) analysis indicates positivity for human epidermal growth factor receptor 2 (HER2). For the assessment of HER2 status, prespecified subgroup analyses were restricted to patients whose tumors had an IHC score of 3+ or fluorescence in situ hybridization (FISH) positive status, since these categories accounted for approximately 90% of patients. CI denotes confidence interval, ER estrogen receptor, and PgR progesterone receptor. 
Crossover Population
No new safety signals were identified among patients in the control group who crossed over to receive pertuzumab. Most events were of grade 1 or 2. Of the 221 events in the crossover group, 7 were grade 3 events, and 2 were grade 4 events (diarrhea and dehydration in the same patient). There was one death from an unknown cause. No symptomatic left ventricular dysfunction was reported after crossover. Two patients had asymptomatic reductions in the LVEF.
Discussion
First-line therapy with pertuzumab, trastuzumab, and docetaxel significantly improved overall survival among patients with HER2-positive metastatic breast cancer, as compared with placebo, trastuzumab, and docetaxel. Since this was an intention-to-treat analysis, patients in the control group who crossed over to receive pertuzumab were included in the control group, a factor that added to the strength of the findings. The between-group separation in the Kaplan-Meier curves occurred early and was maintained over time. Findings in subgroup analyses were consistent with the final results and the results of previous analyses.
We were able to estimate the treatment effect on the basis of a median overall survival of 56.5 months in the pertuzumab group, a duration that is exceptionally long in this population of patients. In previous prospective studies of firstline therapy with trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer, the median overall survival has ranged from 25.1 months to 38.1 months. 9-13 The progression-free survival benefit was also maintained over time in our study. 4, 5 The majority of adverse events occurred during docetaxel treatment. Long-term cardiac safety was maintained, since treatment with pertuzumab did not increase cardiac toxicity (including asymptomatic and symptomatic left ventricular dysfunction), as compared with placebo. Symptoms developed at a later time with pertuzumab and quality of life did not differ from that in the control group during the chemotherapy period in the pertuzumab group. 14 * Percentages are based on the numbers of patients in the intention-to-treat population who received any treatment after the discontinuation of study drugs. Patients who discontinued treatment include 4 patients who were not treated and 17 patients who crossed over to receive pertuzumab and subsequently withdrew from crossover treatment. Preclinical data showed that combining pertuzumab and trastuzumab resulted in greater activity than that with either antibody alone owing to more comprehensive signaling blockade, since the antibodies bind to different HER2 epitopes. 2, 3 The BO17929 study initially showed that the combination of pertuzumab plus trastuzumab was active in patients with advanced breast cancer following progression 15 and subsequently showed that it was the combination, rather than pertuzumab alone, that was responsible for the activity. 16 The efficacy of combination therapy was also shown among patients receiving neoadjuvant therapy, with the use of pertuzumab, trastuzumab, and docetaxel resulting in higher rates of complete response on pathological analysis, as compared with trastuzumab plus docetaxel, pertuzumab plus docetaxel, or pertuzumab plus trastuzumab. 17 These data supported the use of neoadjuvant pertuzumab with trastuzumab and docetaxel in patients with HER2-positive breast cancer, an indication that was recently approved by the Food and Drug Administration. 18 Despite the clinically meaningful survival results in our study, important questions remain to be addressed in this field. First, most deaths in the study were due to breast cancer; therefore, better treatments are still needed. This is particularly important in patients with early disease, such as those in the ongoing Adjuvant Pertuzumab and Herceptin in Initial Therapy of Breast Cancer (APHINITY) trial (ClinicalTrials.gov number, NCT01358877). Second, it is not clear whether hormonal therapy plus pertuzumab and trastuzumab is more effective than hormonal therapy plus trastuzumab alone in patients with hormone receptor-positive disease. Third, there is no biomarker in addition to HER2 that predicts which patients with HER2-positive disease would benefit most from the combination of pertuzumab and trastuzumab. [19] [20] [21] The presence of mutated PIK3CA may indicate an adverse prognosis for patients with metastatic disease but did not have a predictive value in our study. 21 Whether other chemotherapeutic agents could improve on the safety profile is a fourth area for investigation. A phase 2 study assessing progression-free survival at 6 months with pertuzumab, trastuzumab, and paclitaxel showed few grade 3 or 4 adverse events and no cardiac events. 22 Finally, the question of when, if ever, therapy with pertuzumab plus trastuzumab for metastatic breast cancer should be stopped remains unanswered. With trastuzumab, continuing therapy after progression and adding a different chemotherapeutic agent resulted in prolonged progression-free survival, 23 and lapatinib added to trastuzumab was superior to lapatinib monotherapy with respect to progression-free and overall survival. 24 The current recommendation is to discontinue pertuzumab after progression, but clinical trials are warranted to determine the most effective duration of therapy.
This analysis has several limitations. First, patients who crossed over to receive pertuz umab were included in the control group, which Table S1 in the Supplementary Appendix. † The most common events are those that occurred with a frequency of 25% or more overall (including during the docetaxel treatment period) or that differed by 5 percentage points or more in frequency between the two groups overall. ‡ The frequency of this event was at least 5 percentage points greater in the pertuzumab group, as compared with the control group. in the intention-to-treat analysis favored the control group. Even so, the treatment effect favored pertuzumab in sensitivity analyses that excluded the crossover group (hazard ratio, 0.55) and that censored data at the time of the first pertuzumab dose (hazard ratio, 0.63), since data for patients with a good therapeutic response, who had continued to receive study treatment for a long time, were censored or excluded from the control group but not from the pertuzumab group. However, these analyses support the results of the intention-to-treat analysis. Second, although the subgroups were predefined, the analyses were exploratory and not powered for a statistical result. Small numbers of patients and data with wide confidence intervals limited interpretation of data among patients in the subgroup with nonvisceral disease, for example. The hazard ratio for progression-free survival in this subgroup was 0.96 in the primary analysis, 4 with an updated hazard ratio of 0.83. A relatively small proportion of patients in this subgroup died (58 of 178 patients [32.6%] overall), and survival was long, with a median that was not reached in the pertuzumab group and that was 61.5 months in the control group (data not shown). This study included a large proportion of patients with visceral disease. The subgroup of patients who received adjuvant or neoadjuvant trastuzumab was also small, probably because trastuzumab was not widely available for this indication during the recruitment for this trial. However, the hazard ratios for progression-free and overall survival were similar (0.75 and 0.80, respectively), suggesting a treatment benefit in favor of pertuzumab. One retrospective study has shown better outcomes with trastuzumab in patients with metastatic breast cancer who had received no previous adjuvant or neoadjuvant therapy with the drug, 25 whereas a controlled cohort study showed no difference. 26 Further research is therefore needed.
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In conclusion, in patients with HER2-positive metastatic breast cancer, the addition of pertuzumab to trastuzumab and docetaxel, as compared with the addition of placebo, significantly increased the median overall survival to 56.5 months, an improvement of 15.7 months over survival in the control group, and extended the results of previous analyses showing the efficacy of this drug combination.
Supported by F. Hoffmann-La Roche and Genentech. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
We thank Daniel Clyde of Health Interactions for providing writing assistance.
